Actively Recruiting
Accelerated dTMS Smoking Cessation
Led by Waypoint Centre for Mental Health Care · Updated on 2026-04-21
40
Participants Needed
2
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to examine whether a 5-day course of bilateral accelerated deep transcranial magnetic stimulation (aTMS) is a feasible treatment to help adults (18-65) with Tobacco Use Disorder to quit smoking. This study aims to enroll 30-40 participants and will examine treatment tolerability, treatment acceptability, participant retention, and adherence to scheduled treatment sessions. There are two key objectives and hypotheses: Objective 1: To evaluate whether a 1-week course of bilateral aTMS (4 sessions per day for 5 days) is feasible and tolerable as a smoking cessation treatment. Hypothesis 1: Feasibility will be demonstrated by acceptable tolerability, acceptability, retention, and adherence, with a practical target of 30 out of 40 participants completing the treatment. Objective 2: To explore how aTMS affects smoking outcomes, including: * Point-prevalence abstinence at end of treatment and at Weeks 3, 5, and 9. * Prolonged/continuous abstinence at Weeks 13 and 26. * Craving, cigarettes per day, and dependence severity. Hypothesis 2: Participants will show improvements on these outcomes from post-treatment through follow-up.
CONDITIONS
Official Title
Accelerated dTMS Smoking Cessation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Tobacco use disorder as assessed by DSM-5
- Fagerstrom Test of Nicotine Dependence (FTND) score of 4 or higher
- Motivation to quit smoking within 30 days with a Contemplation Ladder score of 7 or higher
- Signed and dated informed consent form
- Willingness to comply with all study procedures
- Able to communicate in English
You will not qualify if you...
- Smoking abstinence reported in the 3 months before screening
- Current use of other smoking cessation aids
- Contraindications to repetitive transcranial magnetic stimulation (rTMS)
- Pregnancy, trying to become pregnant, or breastfeeding
- Current or recent cerebrovascular disease
- Unstable major psychiatric disorders preventing study participation
- Serious medical or neurological conditions preventing inclusion
- Personal or family history of seizures
- Use of medications lowering seizure threshold, such as clozapine
- Use of more than 2 mg lorazepam or any anticonvulsants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Waypoint Centre for Mental Health Care
Penetanguishene, Ontario, Canada
Actively Recruiting
2
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Not Yet Recruiting
Research Team
F
Florence Tang, MA
CONTACT
V
Vincent Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here